Review
Published on 10 Mar 2023
Recent advances in antigen targeting to antigen-presenting cells in veterinary medicine
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1080238
- 5,104 views
- 5 citations
Type at least 3 characters
2,749 articles
Articles
Study Protocol
Published on 10 Mar 2023
An experimental medicine decipher of a minimum correlate of cellular immunity: Study protocol for a double-blind randomized controlled trial
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1135979
- 1,778 views
- 1 citation
Original Research
Published on 09 Mar 2023
Immunization with Tp0954, an adhesin of Treponema pallidum, provides protective efficacy in the rabbit model of experimental syphilis
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1130593
- 2,231 views
- 4 citations
Original Research
Published on 09 Mar 2023
Antibody response to different COVID-19 vaccines among the migrant workers of Bangladesh
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1128330
- 2,920 views
- 1 citation
Brief Research Report
Published on 09 Mar 2023
A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1135815
- 13,207 views
- 6 citations
Review
Published on 09 Mar 2023
Oral route lipopolysaccharide as a potential dementia preventive agent inducing neuroprotective microglia
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1110583
- 3,532 views
- 4 citations
Original Research
Published on 07 Mar 2023
Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1131229
- 2,793 views
- 7 citations
Systematic Review
Published on 07 Mar 2023
Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1090533
- 3,111 views
- 2 citations
Correction
Published on 07 Mar 2023
Corrigendum: SARS-CoV-2 antibody response after mRNA vaccination in healthcare workers with and without previous COVID-19, a follow-up study from the University Hospital in Krakow, Poland
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1155871
- 880 views
Brief Research Report
Published on 06 Mar 2023
Immune response to BNT162b2 SARS-CoV-2 vaccine in patients living with HIV: The COVIH-DAPT study
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1136723
- 1,850 views
- 2 citations
Original Research
Published on 06 Mar 2023
Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1106837
- 2,915 views
- 9 citations
Systematic Review
Published on 03 Mar 2023
A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1113156
- 11,876 views
- 25 citations
Original Research
Published on 03 Mar 2023
Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1107866
- 1,893 views
- 7 citations
Clinical Trial
Published on 02 Mar 2023
Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1152695
- 2,212 views
- 7 citations
Original Research
Published on 02 Mar 2023
Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1139980
- 2,307 views
- 9 citations
Original Research
Published on 02 Mar 2023
Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2023.1120556
- 3,335 views
- 10 citations